Kyowa Kirin Co., Ltd.

4151.T
Drug Manufacturers - Specialty & Generic
2026/08/03 Updated
Market Cap: $8.5B (¥1.3T)
Stock Price: $16.17 (¥2,555)
Exchange Rate: 1 USD = ¥157.98

Financial Summary Supplement — Interim Financial Results for the Fiscal Year Ending December 2026, Q2

Discloses consolidated performance and cash flow trends for the second quarter of the fiscal year ending December 2026. Revenue by region and by product is shown, along with trends in core operating margin and R&D intensity. Forward guidance is provided with notes.

Importance:
Page Updated: August 3, 2026
IR Disclosure Date: August 3, 2026

Key Figures

  • Net revenue: Unknown
  • Core operating profit margin: Unknown
  • Region-by-region net revenue: Unknown
  • Major product sales: Unknown
  • R&D expense ratio: Unknown

AI要約

Performance Overview

This document is prepared as a supplement to the financial results for the second quarter of the fiscal year ending December 2026, covering consolidated income statement trends, region-by-region revenue, major product sales composition, and development pipeline. It presents quarterly and cumulative data for revenue, cost structure, pre-tax income, and core metrics, with accompanying trend charts for selling, general and administrative expenses and R&D costs. FX information is listed separately, divided into 2026 actuals and projections.

Outlook and Impact for Investors

Progress indicators for quarterly and year-to-date performance are provided, with supporting figures and ratios for the 2026 forecast. However, the document does not disclose actual figures in detail, so further disclosures are awaited. R&D expense ratio is an important metric, and metrics such as core EPS are mentioned, but some figures remain unknown.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

Kowa Kirin Company, Limited

Company overview · Stock price · Financial data · All IR

View company page →